# CentraleSupélec Venture

> CentraleSupélec Venture is a VC fund in Paris backing Medical and Biotechnology. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 8
- Last investment: Jul 2026
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/centralesupelecventure/

CentraleSupélec Venture is a VC fund in Paris focused on Medical and Biotechnology. CentraleSupélec Venture est un fonds de capital-risque early-stage, créé par l’Ecole CentraleSupélec.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $412k–$4.3M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 38% |
| Biotechnology | 2 | 25% |
| B2B | 1 | 13% |
| SaaS | 1 | 13% |
| Genetics | 1 | 13% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 7 | 88% |
| Pre-Seed | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| En Carta Diagnostics | En Carta Diagnostics develops molecular diagnostic technologies that enable the rapid detection of DNA and RNA pathogens at the point of care. The company designs programmable diagnostic platforms that deliver laboratory-grade molecular testing without requiring specialized equipment or extensive technical training. Its technology uses syntheticbiology and portable diagnostic devices to support the detection of infectious diseases, including Lyme disease, as well as other bacterial and viral pathogens. En Carta Diagnostics also develops custom molecular diagnostic solutions and expands its platform to address a broad range of genetic and infectious disease applications. The company collaborates with research institutions and applies its proprietary diagnostic technology to improve the accessibility and reliability of molecular testing across healthcare settings. | $3.4M | Seed | Jul 10, 2026 | https://www.encarta.bio/ |
| Rewake | Rewake is a refurbishing company that offers laboratories with reconditioned equipment and instruments at half the price of new to make them usable again. | $412.2K | Seed | Jan 14, 2025 | https://rewake.fr |
| Trace For Good | Trace For Good is a traceability and social and environmental data management platform that allows retail businesses to engage with their suppliers using a single source of information. | $3.7M | Seed | Nov 12, 2024 | https://www.traceforgood.com/ |
| Highcast | Dans un contexte de transition énergétique et d’augmentation structurelle des prix, bien suivre et prévoir vos consommations en énergie devient un enjeu majeur. Chez Highcast, nous voulons relever ce défi autour de 3 axes : - Maîtriser et expliquer votre budget - Contribuer à la transition énergétique - Optimiser vos approvisionnements | $2.2M | Seed | Oct 09, 2024 | https://www.highcast.co |
| En Carta Diagnostics | En Carta Diagnostics develops molecular diagnostic technologies that enable the rapid detection of DNA and RNA pathogens at the point of care. The company designs programmable diagnostic platforms that deliver laboratory-grade molecular testing without requiring specialized equipment or extensive technical training. Its technology uses syntheticbiology and portable diagnostic devices to support the detection of infectious diseases, including Lyme disease, as well as other bacterial and viral pathogens. En Carta Diagnostics also develops custom molecular diagnostic solutions and expands its platform to address a broad range of genetic and infectious disease applications. The company collaborates with research institutions and applies its proprietary diagnostic technology to improve the accessibility and reliability of molecular testing across healthcare settings. | $1.6M | Pre-Seed | May 22, 2024 | https://www.encarta.bio/ |
| Scienta Lab | Scienta Lab is an AI-powered platform pioneering Precision Immunology | $4.3M | Seed | Dec 05, 2023 | https://www.scientalab.com |
| KOLIBRI | In the biotech space, cell and gene therapy and clean meat are two of the most promising industries. Yet both are facing the same issue: large-scale cell culture remains the blocking point to scale up and make both cell and gene therapies and clean meat accessible and affordable. To that end, Kolibri is building a proprietary cell-engineeringplatform, combining cutting edge techniques in acoustics and biology, allowing for a 90x higher yield while decreasing production costs up to 50x. | $2.8M | Seed | Mar 06, 2023 | https://kolibrilab.com |
| Exwayz | Exwayz is a software development platform that specializes in real-time 3D LiDAR processing solutions. | $1.2M | Seed |  | https://www.exwayz.fr |

8 of 8 investments shown.

## Co-investors
- [Hi Inov - Dentressangle](https://shizune.co/investors/profile/hi-inov) — VC Fund, 2 deals together
- [50 Partners Health](https://shizune.co/investors/profile/50-partners-health) — VC Fund, 1 deal together
- [AFI Ventures](https://shizune.co/investors/profile/afi-ventures) — VC Fund, 1 deal together
- [Ankaa Ventures](https://shizune.co/investors/profile/ankaa-ventures) — VC Fund, 1 deal together
- [Blue Forest Ventures](https://shizune.co/investors/profile/blue-forest-ventures) — VC Fund, 1 deal together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Medical Investors in France](https://shizune.co/investors/medical-investors-france)
- [Medical VC Funds in France](https://shizune.co/investors/medical-vc-funds-france)

## FAQ

### What does CentraleSupélec Venture invest in?

CentraleSupélec Venture invests primarily in Medical, Biotechnology and B2B startups, most often at Seed and Pre-Seed stage. Most of the 8 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is CentraleSupélec Venture's check size?

CentraleSupélec Venture typically joins rounds of $412k–$4.3M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds CentraleSupélec Venture participates in.

### When did CentraleSupélec Venture last invest?

The most recent investment recorded for CentraleSupélec Venture closed in Jul 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co